NO317097B1 - N-benzyl-3-indenylacetamidderivater for behandling av neoplasi - Google Patents
N-benzyl-3-indenylacetamidderivater for behandling av neoplasi Download PDFInfo
- Publication number
- NO317097B1 NO317097B1 NO20002972A NO20002972A NO317097B1 NO 317097 B1 NO317097 B1 NO 317097B1 NO 20002972 A NO20002972 A NO 20002972A NO 20002972 A NO20002972 A NO 20002972A NO 317097 B1 NO317097 B1 NO 317097B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- hydrogen
- alkyl
- fluoro
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/989,353 US5948779A (en) | 1997-12-12 | 1997-12-12 | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
| US09/206,245 US6066634A (en) | 1997-12-12 | 1998-12-07 | Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia |
| PCT/GB1998/003712 WO1999031065A1 (en) | 1997-12-12 | 1998-12-11 | N-benzyl-3-indenylacetamides derivatives for treating neoplasia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20002972D0 NO20002972D0 (no) | 2000-06-09 |
| NO20002972L NO20002972L (no) | 2000-08-09 |
| NO317097B1 true NO317097B1 (no) | 2004-08-09 |
Family
ID=26901185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002972A NO317097B1 (no) | 1997-12-12 | 2000-06-09 | N-benzyl-3-indenylacetamidderivater for behandling av neoplasi |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6166053A (https=) |
| EP (1) | EP1044187B1 (https=) |
| JP (1) | JP4307719B2 (https=) |
| CN (1) | CN100436418C (https=) |
| AT (1) | ATE257152T1 (https=) |
| AU (1) | AU752072B2 (https=) |
| BR (1) | BR9813540A (https=) |
| CA (1) | CA2314339C (https=) |
| CZ (1) | CZ298826B6 (https=) |
| DE (1) | DE69820908T2 (https=) |
| ES (1) | ES2212383T3 (https=) |
| HU (1) | HU227153B1 (https=) |
| IL (1) | IL136603A0 (https=) |
| NO (1) | NO317097B1 (https=) |
| NZ (1) | NZ504958A (https=) |
| PL (1) | PL196936B1 (https=) |
| TR (1) | TR200001687T2 (https=) |
| WO (1) | WO1999031065A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257152T1 (de) * | 1997-12-12 | 2004-01-15 | Osi Pharm Inc | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia |
| IL132366A0 (en) * | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
| JP2004500425A (ja) * | 2000-04-19 | 2004-01-08 | リリー アイコス リミテッド ライアビリティ カンパニー | パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用 |
| DE10058663A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| WO2002067936A1 (en) * | 2001-02-21 | 2002-09-06 | Cell Pathways, Inc. | Methods for treatment of inflammatory bowel disease |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| US20030073740A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of lupus erythematosus |
| US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
| US6479493B1 (en) * | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
| CN100398522C (zh) * | 2003-08-20 | 2008-07-02 | Irm责任有限公司 | 组织蛋白酶s的抑制剂 |
| US6995622B2 (en) * | 2004-01-09 | 2006-02-07 | Robert Bosh Gmbh | Frequency and/or phase compensated microelectromechanical oscillator |
| JP2008501407A (ja) | 2004-06-02 | 2008-01-24 | メリット ダイアモンド コーポレイション | 装身具のための快適な内側およびその内側を備える装身具 |
| CN1332930C (zh) * | 2005-08-05 | 2007-08-22 | 中国科学院上海有机化学研究所 | 制备乙氰菊酯前体的方法 |
| US8044048B2 (en) * | 2006-01-04 | 2011-10-25 | Southern Research Institute | Derivatives of sulindac, use thereof and preparation thereof |
| WO2009022756A1 (ja) * | 2007-08-13 | 2009-02-19 | Katayama Chemical Industries Co., Ltd. | 虚血性疾患の診断及び治療 |
| WO2010053910A1 (en) * | 2008-11-04 | 2010-05-14 | Wellstat Therapeutics Corporation | Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids |
| JP2013501665A (ja) | 2009-08-07 | 2013-01-17 | オークランド ユニサービシズ リミテッド | 道路から電気エネルギーを得る電気車両システム |
| US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
| US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
| JP7169008B2 (ja) | 2018-04-26 | 2022-11-10 | エーディーティー ファーマシューティカルズ，エルエルシー | 抗がんインデン、インダン、アザインデン、アザインダン、医薬組成物および使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650720B2 (en) * | 1991-03-08 | 1994-06-30 | Fgn, Inc. | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof |
| US6063818A (en) * | 1996-06-13 | 2000-05-16 | Cell Pathways Inc. | Substituted benzylidene indenyl formamides, acetamides and propionamides |
| ATE257152T1 (de) * | 1997-12-12 | 2004-01-15 | Osi Pharm Inc | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia |
| US5948779A (en) * | 1997-12-12 | 1999-09-07 | Cell Pathways, Inc. | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
-
1998
- 1998-12-11 AT AT98959050T patent/ATE257152T1/de not_active IP Right Cessation
- 1998-12-11 JP JP2000538992A patent/JP4307719B2/ja not_active Expired - Fee Related
- 1998-12-11 DE DE69820908T patent/DE69820908T2/de not_active Expired - Lifetime
- 1998-12-11 CA CA002314339A patent/CA2314339C/en not_active Expired - Fee Related
- 1998-12-11 CN CNB988118955A patent/CN100436418C/zh not_active Expired - Fee Related
- 1998-12-11 WO PCT/GB1998/003712 patent/WO1999031065A1/en not_active Ceased
- 1998-12-11 NZ NZ504958A patent/NZ504958A/xx unknown
- 1998-12-11 EP EP98959050A patent/EP1044187B1/en not_active Expired - Lifetime
- 1998-12-11 HU HU0100170A patent/HU227153B1/hu not_active IP Right Cessation
- 1998-12-11 IL IL13660398A patent/IL136603A0/xx active IP Right Grant
- 1998-12-11 TR TR2000/01687T patent/TR200001687T2/xx unknown
- 1998-12-11 BR BR9813540-6A patent/BR9813540A/pt not_active Application Discontinuation
- 1998-12-11 CZ CZ20002157A patent/CZ298826B6/cs not_active IP Right Cessation
- 1998-12-11 PL PL341151A patent/PL196936B1/pl not_active IP Right Cessation
- 1998-12-11 ES ES98959050T patent/ES2212383T3/es not_active Expired - Lifetime
- 1998-12-11 AU AU14981/99A patent/AU752072B2/en not_active Ceased
-
2000
- 2000-01-24 US US09/490,269 patent/US6166053A/en not_active Expired - Lifetime
- 2000-06-09 NO NO20002972A patent/NO317097B1/no not_active IP Right Cessation
- 2000-12-20 US US09/741,970 patent/US6426349B1/en not_active Expired - Fee Related
-
2002
- 2002-07-26 US US10/206,687 patent/US6610854B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6610854B2 (en) | 2003-08-26 |
| CZ298826B6 (cs) | 2008-02-20 |
| US20030009033A1 (en) | 2003-01-09 |
| US6166053A (en) | 2000-12-26 |
| EP1044187B1 (en) | 2004-01-02 |
| NO20002972L (no) | 2000-08-09 |
| AU752072B2 (en) | 2002-09-05 |
| PL196936B1 (pl) | 2008-02-29 |
| JP4307719B2 (ja) | 2009-08-05 |
| EP1044187A1 (en) | 2000-10-18 |
| IL136603A0 (en) | 2001-06-14 |
| WO1999031065A1 (en) | 1999-06-24 |
| PL341151A1 (en) | 2001-03-26 |
| NO20002972D0 (no) | 2000-06-09 |
| US6426349B1 (en) | 2002-07-30 |
| NZ504958A (en) | 2003-03-28 |
| CZ20002157A3 (cs) | 2000-10-11 |
| HUP0100170A3 (en) | 2001-12-28 |
| CN100436418C (zh) | 2008-11-26 |
| HUP0100170A1 (hu) | 2001-07-30 |
| DE69820908D1 (de) | 2004-02-05 |
| CA2314339A1 (en) | 1999-06-24 |
| CN1281436A (zh) | 2001-01-24 |
| AU1498199A (en) | 1999-07-05 |
| BR9813540A (pt) | 2000-10-10 |
| ATE257152T1 (de) | 2004-01-15 |
| DE69820908T2 (de) | 2004-12-23 |
| JP2002508358A (ja) | 2002-03-19 |
| HU227153B1 (en) | 2010-08-30 |
| CA2314339C (en) | 2009-09-08 |
| TR200001687T2 (tr) | 2000-10-23 |
| ES2212383T3 (es) | 2004-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO317097B1 (no) | N-benzyl-3-indenylacetamidderivater for behandling av neoplasi | |
| US6066634A (en) | Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia | |
| US6211177B1 (en) | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives | |
| US20200062732A1 (en) | Dna-pk inhibitors | |
| TW201127823A (en) | Indole based receptor CRTH2 antagonists | |
| TW201022216A (en) | Compounds, compositions and methods of using same for modulating uric acid levels | |
| ES2238324T3 (es) | Derivados heterocicloalquilsulfonilpirazol como agentes antiinflamatorios/analgesicos. | |
| RS57306B1 (sr) | Inhibitori dnk-pk | |
| TW200808771A (en) | Novel compounds II | |
| JP2000514417A (ja) | 置換ベンジリデンインデニルホルムアミド、アセタミドおよびプロピオンアミド | |
| US6028116A (en) | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia | |
| US6486158B1 (en) | [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia | |
| US20020028936A1 (en) | 1,3-disubstituted indolin-2-ones for neoplasia | |
| WO2013159698A1 (zh) | 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用 | |
| CN120309588A (zh) | 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途 | |
| HK1030947B (en) | N-benzyl-3-indenylacetamides derivatives for treating neoplasia | |
| US20010051651A1 (en) | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |